Search

Your search keyword '"Halfvarson, Jonas"' showing total 204 results

Search Constraints

Start Over You searched for: Author "Halfvarson, Jonas" Remove constraint Author: "Halfvarson, Jonas" Database Unpaywall Remove constraint Database: Unpaywall
204 results on '"Halfvarson, Jonas"'

Search Results

2. Histologic Activity in Inflammatory Bowel Disease and Risk of Serious Infections: A Nationwide Study

7. Disease signatures in the gut metagenome of a prospective family cohort of inflammatory bowel disease

10. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

13. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

14. Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations

19. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

23. Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis

24. Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

25. Bidirectional Mendelian Randomisation Analysis Provides Evidence for the Causal Involvement of Dysregulation of CXCL9, CCL11 and CASP8 in the Pathogenesis of Ulcerative Colitis

26. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

30. Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study

34. Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis

38. Tu1545: TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE

39. Sa1583: SERUM PROTEOMIC MARKERS THAT PREDICT FUTURE CROHN'S DISEASE DEVELOPMENT ARE ASSOCIATED WITH GUT BARRIER FUNCTION, SUBCLINICAL GUT INFLAMMATION AND IMMUNE RESPONSE TO BACTERIAL ANTIGENS

41. Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort

44. OMO-1 Epigenetic alterations in IBD: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome

47. Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply

48. Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Catalog

Books, media, physical & digital resources